The DOI matches its Crossref record; 295 of the 299 references it cites were found in a registry or an index.
Interpretation of the evidence for the efficacy and safety of statin therapy
Open accessAbstract
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention). Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger absolute benefits would accrue with more prolonged therapy, and these benefits persist long term. The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke. Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes. However, any adverse impact of these side-effects on major vascular events has already been taken into account in the estimates of the absolute benefits. Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% absolute harm) per 10 000 treated for 5 years. However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution). The large-scale evidence available from randomised trials also indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery. Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events. For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
In the citing paper
“Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77-0.81) per 1.0 mmoL/L reduction in LDL-C”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“However, since the absolute risk of CAD is higher in older persons, the associated absolute increase in risk for a given increment in TC is larger with increasing age [217].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“The relative reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease, but appeared smaller among older individuals not known to have vascular disease.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Research works printed but not linked: 3
- Abramson, 2013, Don't Give More Patients Statins, The New York Times
- 2013, Statins can weaken muscles and joints: cholesterol drug raises risk of problems by up to 20 per cent, MailOnline
- 2016, How Big Pharma greed is killing tens of thousands around the world: Patients are over-medicated and often given profitable drugs with ‘little proven benefits,’ leading doctors warn, MailOnline
Cited by
Sorted by citations
Items 601–700 of 1,000
Kuhlman, A. B., Morville, T. H., Dohlmann, T. L., Hansen, M., Kelly, B., Helge, J. W., & Dela, F. (2018) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0488 · Cited by 19
Amarenco, P., Kim, J. S., Labreuche, J., Giroud, M., Lee, B., Mahagne, M., Nighoghossian, N., Simon, T., Steg, P. G., Touboul, P., et al. (2019) · European Stroke Journal · doi:10.1177/2396987319838100 · Cited by 20
Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study
Yang, Z., Edwards, D., Massou, E., Saunders, C. L., Brayne, C., & Mant, J. (2019) · Clinical Epidemiology · doi:10.2147/clep.s201983 · Cited by 19
Habte, M. L., Seifu, D., Degef, M., Menon, M. K., Yifter, H., & Feyisa, T. O. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s234382 · Cited by 19
Bhagavathula, A. S., Matrooshi, N. O. A., Clark, C. C. T., & Rahmani, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00989-1 · Cited by 20
Rea, F., Mancia, G., & Corrao, G. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa126 · Cited by 19
Moreno-Arellano, S., Delgado-de-Mendoza, J., & Santi-Cano, M. J. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.03.012 · Cited by 19
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
Schlackow, I., Kent, S., Herrington, W. G., Emberson, J., Haynes, R., Reith, C. A., Collins, R., Landray, M., Gray, A. M., Baigent, C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.028 · Cited by 19
Self-citationJia, X., Rifai, M. A., Birnbaum, Y., Smith, S. C., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0784-8 · Cited by 19
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Wu, L., Zhang, B., Li, C., Zhuang, Z., Liu, K., Chen, H., Zhu, S., Zhu, J., Dai, Z., Huang, H., et al. (2024) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-332392 · Cited by 18
Khoo, T., Tan, E., Limaye, V. S., Gunawardena, H., Sadler, R., Lamb, J. A., Lyu, X., Brusch, A. M., Needham, M., Austin, K., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf238 · Cited by 21
Personalised Medicine Approaches to Screening and Prevention
Gaitskell, K. L. (2017) · The New Bioethics · doi:10.1080/20502877.2017.1314884 · Cited by 18
Gupta, A., Thompson, D., Whitehouse, A., Collier, T. J., Dahlöf, B., Poulter, N. R., Collins, R., Sever, P., & A RUGBE Investigators (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.14.12 · Cited by 18
Self-citationSoran, H., France, M. W., Adam, S., Iqbal, Z., Ho, J. H., & Durrington, P. N. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.06.023 · Cited by 18
Ferrières, J., Bataille, V., Puymirat, É., Schiele, F., Simon, T., Danchin, N., & for the FAST‐MI investigators (2020) · Clinical Cardiology · doi:10.1002/clc.23437 · Cited by 18
Marcusa, D. P., Giugliano, R. P., Park, J., de Lemos, J. A., Cannon, C. P., & Sabatine, M. S. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6184 · Cited by 18
Li, N., Guo, X., Zhou, J., Yan, X., & Yu, F. (2021) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-021-00362-z · Cited by 18
Bell, A. S., Rosoff, D. B., Mavromatis, L. A., Jung, J., Wagner, J., & Lohoff, F. W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026122 · Cited by 19
DEHMER, G. J., Grines, C. L., Bakaeen, F. G., Beasley, D. L., Beckie, T. M., Boyd, J. H., Cigarroa, J. E., Das, S. R., Diekemper, R. L., Frampton, J., et al. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000121 · Cited by 18
Laminarin Reduces Cholesterol Uptake and NPC1L1 Protein Expression in High-Fat Diet (HFD)-Fed Mice
He, Z., Zhang, Z., Xu, P., Dirsch, V. M., Wang, L., & Wang, K. (2023) · Marine Drugs · doi:10.3390/md21120624 · Cited by 18
Quality of life in patients with statin intolerance: a multicentre prospective registry study
Stürzebecher, P. E., Gouni‐Berthold, I., Mateev, C., Frenzel, O., Erbe, S., Boeckel, J., Scholz, M. R., Schatz, U., Weingärtner, O., Kassner, U., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100981 · Cited by 19
Characterizing the genetic architecture of drug response using gene-context interaction methods
Sadowski, M., Thompson, M., Mefford, J., Haldar, T., Oni‐Orisan, A., Border, R., Pazokitoroudi, A., Cai, N., Ayroles, J. F., Sankararaman, S., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100722 · Cited by 19
Byrne, P., Cullinan, J., Gillespie, P., Perera, R., & Smith, S. M. (2019) · British Journal of General Practice · doi:10.3399/bjgp19x702701 · Cited by 17
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects
Li, J., Liu, H.-H., Wu, N., Yeo, K. K., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Baek, S. H., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802426 · Cited by 19
Zhou, E., Li, Z., Nakashima, H., Choukoud, A., Kooijman, S., Berbée, J. F. P., Rensen, P. C. N., & Wang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105524 · Cited by 18
LDL Cholesterol Targets after Ischemic Stroke
Amarenco, P., & Kim, J. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001195 · Cited by 18
Kamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Mondal, S., Bhattacharya, S., & Kalra, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.013 · Cited by 17
Talic, S., Marquina, C., Ofori‐Asenso, R., Liew, D., Owen, A. J., Petrova, M., Lybrand, S., Thomson, D., Ilomäki, J., Ademi, Z., et al. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100880 · Cited by 17
Trimarco, V., Izzo, R., Gallo, P., Manzi, M. V., Forzano, I., Pacella, D., Santulli, G., & Trimarco, B. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001878 · Cited by 18
Zoungas, S., Moran, C., Curtis, A. J., Spark, S., Flanagan, Z., Beilin, L. J., Chong, T. T. ‐., CLOUD, G. C., Hopper, I., Kost, A., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036357 · Cited by 18
Kim, Y. H., Her, A., Jeong, M. H., Kim, B., Shin, D., Kim, J., Ko, Y., Choi, D., Hong, M., & Jang, Y. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27985 · Cited by 17
Huang, J., Du, J., Lin, W., Long, Z., Zhang, N., Huang, X., Xie, Y., Liu, L., & Ma, W. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.003 · Cited by 15
Mo, J., Chen, Z., Xu, J., Wang, A., Meng, X., Zhao, X., Li, H., Wu, S., & Wang, Y. (2020) · Aging · doi:10.18632/aging.103365 · Cited by 17
Xu, W., & Zhou, Y. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06065-z · Cited by 17
Stroke Prevention: Little-Known and Neglected Aspects
Azarpazhooh, M. R., Bogiatzi, C., & Spence, J. D. (2021) · Cerebrovascular Diseases · doi:10.1159/000515829 · Cited by 18
Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis
Tsui, L., Ye, P., Xu, S., Yuan, L., Chen, B., Chen, S.-P., & Cheng, R.-Y. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2022-003333 · Cited by 17
Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways
Silva, L. F., Ravi, R., Vangipurapu, J., & Laakso, M. (2022) · Metabolites · doi:10.3390/metabo12080753 · Cited by 17
Zhu, B., Ren, H., Xie, F., An, Y., Wang, Y., & Tan, Y. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220919085019 · Cited by 18
Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise
Dunphy, L., Morhij, R., & Tucker, S. C. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-218942 · Cited by 17
PCSK9 Inhibition to Reduce Cardiovascular Risk
Waters, D. D., & Hsue, P. Y. (2017) · Circulation Research · doi:10.1161/circresaha.117.311015 · Cited by 17
Coaching Patients Saves Lives and Money
Byrnes, J., Elliott, T. M., Vale, M. J., Jelinek, M. V., & Scuffham, P. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.10.019 · Cited by 17
Medication management in older adults
Kim, L. D., Koncilja, K., & Nielsen, C. D. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.16109 · Cited by 20
Statin Use Over 65 Years of Age and All‐Cause Mortality: A 10‐Year Follow‐Up of 19 518 People
Eilat‐Tsanani, S., Mor, E., & Schonmann, Y. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16060 · Cited by 16
on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0545-2 · Cited by 16
Self-citationCombined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction
Ritchie, S. C., Jiang, X., Pennells, L. A. M., Xu, Y., Coffey, C., Liu, Y., Gibson, J. T., Surendran, P., Karthikeyan, S., Lambert, S. A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf947 · Cited by 19
Self-citationSimvastatin and non‐segmental vitiligo: A new potential treatment option?
Shaker, E. S. E., Allam, S. H., Mabrouk, M. M., El-Gharbawy, N. M., & Salaam, S. F. A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15969 · Cited by 16
Dai, Y., Chen, Q., Zhang, D., Li, M., & Liu, W. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02014-2 · Cited by 18
Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures
Scattolini, V., Luni, C., Zambon, A., Galvanin, S., Gagliano, O., Ciubotaru, C. D., Avogaro, A., Mammano, F., Elvassore, N., & Fadini, G. P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0210-y · Cited by 16
Strategies to manage cardiovascular risk in chronic kidney disease
Mark, P. B. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx329 · Cited by 17
Herrett, E. L., Williamson, E., Beaumont, D., Prowse, D., Youssouf, N. F., Brack, K. E., Armitage, J., Goldacre, B. M., MacDonald, T. M., van Staa, T. P., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016604 · Cited by 16
Self-citationStatins increase the risk of herpes zoster: A propensity score-matched analysis
Kim, M., Yun, S., Lee, S., Choi, S., Kim, Y. S., Woo, J. H., & Kim, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198263 · Cited by 16
Approximate Mortality Risks between Hyperuricemia and Diabetes in the United States
Chen, P.-H., Chen, Y.-W., Liu, W.-J., Hsu, S., Chen, C., & Lee, C.-L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122127 · Cited by 16
Hero, C., Karlsson, S. A., Franzén, S., Svensson, A., Miftaraj, M., Guðbjörnsdóttir, S., Sundell, K. A., Eliasson, B., & Eeg‐Olofsson, K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000719 · Cited by 17
Thomas, J. P., Loke, Y. K., & Alexandre, L. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02967-0 · Cited by 17
Kim, H., Lee, C. J., Pak, H., Kim, D., Rhee, M., Lee, B. K., Ahn, Y., Cho, B. R., Woo, J., Hur, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75901-0 · Cited by 16
Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides
Harbour, V., Casillas, C., Siddiqui, Z., Sarkar, B., Sanyal, S., Nguyen, P. K., Kim, K. K., Roy, A., Iglesias-Montoro, P., Patel, S., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01229 · Cited by 16
Warita, K., Ishikawa, T., Sugiura, A., Tashiro, J., Shimakura, H., Hosaka, Y. Z., Ohta, K., Warita, T., & Oltvai, Z. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-91928-3 · Cited by 16
State of the Art: Therapie mit Statinen
Laufs, U., Weingärtner, O., Kassner, U., & Schatz, U. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2471 · Cited by 16
Türkmen, D., Masoli, J. A. H., Kuo, C., Bowden, J., Melzer, D. R., & Pilling, L. C. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15245 · Cited by 18
Sung, F., Jong, Y.-C., Muo, C., Hsu, C., Tsai, W., & Hsu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.815882 · Cited by 15
Metabolic Strategies in Healthcare: A New Era
Phillips, M. C. L. (2022) · Aging and Disease · doi:10.14336/ad.2021.1018 · Cited by 16
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes
Bosch, J., O'Donnell, M. J., Gao, P., Joseph, P. G., Pais, P. S., Xavier, D., Dans, A. M. L., López-Jaramillo, P. A., & Yusuf, S. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5088 · Cited by 16
Self-citationEvidence for more intensive cholesterol lowering
Soran, H., Kwok, S., Adam, S., Ho, J. H., & Durrington, P. N. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000433 · Cited by 16
Wang, Y., Wang, J., & Wang, S. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0270-7 · Cited by 16
Jaspers, N. E. M., Visseren, F. L. J., Numans, M. E., Smulders, Y. M., Martinet, F. A. V. L., van der Graaf, Y., & Dorresteijn, J. A. N. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021309 · Cited by 16
Statin treatment and increased diabetes risk. Possible mechanisms
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.12.001 · Cited by 16
Turner, R. M., Fontana, V., Fitzgerald, R. J., Morris, A. P., & Pirmohamed, M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14133 · Cited by 17
Liu, M., Peng, J., Guo, Y., Wu, N., Zhu, C., Gao, Y., Dong, Q., & Li, J. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab042 · Cited by 16
Alqasrawi, M. N., Al-Mahayri, Z. N., Albawa’neh, A. S., Khasawneh, L. Q., Dabaghie, L., Altoum, S. M., Hamza, D., Misra, V., Ouda, H. Z., Aburuz, S., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00753-6 · Cited by 15
Llanes, E. J. B., Thongtang, N., Lee, Z.-V., Hoa, T., Yee, O. H., & Sukmawan, R. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101019 · Cited by 15
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 19
The impact of lipid-lowering medications on coronary artery plaque characteristics
Pulipati, V. P., & Alenghat, F. J. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100294 · Cited by 16
Global research trends in atherosclerosis: A bibliometric and visualized study
Tian, W., Zhang, T., Wang, X., Zhang, J., Ju, J., & Xu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.956482 · Cited by 18
Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy
Davis, J. W., Weller, S. C., Porterfield, L. R., Chen, L., & Wilkinson, G. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.48213 · Cited by 16
Apetroaei, M.-M., Fragkiadaki, P., Velescu, B. Ș., Baliou, S., Renieri, E. A., Dinu‐Pîrvu, C. E., Drăgănescu, D., Vlasceanu, A.-M., Nedea, M. I., Udeanu, D. I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147694 · Cited by 17
Kalbacher, D., Waldeyer, C., Blankenberg, S., & Westermann, D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.08.03 · Cited by 16
An updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Rhee, M., Kim, K.-J., Kim, S., Yoon, Y. W., Rha, S., Hong, S. J., Kwak, C. H., Kim, W., Nam, C., Park, T., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.10.010 · Cited by 15
Krogh, H. W., Svendsen, K., Igland, J., Mundal, L. J., Holven, K. B., Bogsrud, M. P., Leren, T. P., & Retterstøl, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55682-x · Cited by 15
Management of asymptomatic carotid stenosis
Spence, J. D. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-975 · Cited by 15
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity
Moșteoru, S., Gaiță, D. I., & Banach, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1828343 · Cited by 15
PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2021) · Archives of Medical Science · doi:10.5114/aoms/127226 · Cited by 15
Self-citationNutraceuticals for the Control of Dyslipidaemias in Clinical Practice
Penson, P. E., & Banach, M. (2021) · Nutrients · doi:10.3390/nu13092957 · Cited by 16
Alghamdi, A. A., Balkhi, B. S., Altowaijri, A. I., Alshehri, N., Ralph, L., Marriott, E.-R., Urbich, M., Aljanad, F., & Aziziyeh, R. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00300-8 · Cited by 15
Huang, Y.-C., Lee, J.-D., Weng, H., Lin, L.-C., Tsai, Y., & Yang, J. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-054381 · Cited by 15
Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering
Rodríguez, F., & Harrington, R. A. (2016) · JAMA · doi:10.1001/jama.2016.16575 · Cited by 15
Statins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 18
More- Versus Less-Intensive Lipid-Lowering Therapy
Toyota, T., Morimoto, T., Yamashita, Y., Shiomi, H., Kato, T., Makiyama, T., Nakagawa, Y., Saito, N., Shizuta, S., Ono, K., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005460 · Cited by 15
Gündüz, C., Başoğlu, Ö. K., Kvamme, J. A., Verbraecken, J. A., Anttalainen, U., Marrone, O., Steiropoulos, P., Roisman, G. L., Joppa, P., Hein, H., et al. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.02.023 · Cited by 15
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 16
Lavie, G., Hoshen, M., Leibowitz, M., Benis, A., Akriv, A., Balicer, R. D., & Reges, O. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.09.058 · Cited by 15
Valgimigli, M. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy872 · Cited by 16
Bempedoic Acid for Lowering LDL Cholesterol
Honigberg, M. C., & Natarajan, P. (2019) · JAMA · doi:10.1001/jama.2019.16598 · Cited by 16
Pate, A., Emsley, R., & van Staa, T. P. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x713057 · Cited by 14
Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs
O'Toole, T. E., Kelsey, M. D., Shah, N. P., McGarrah, R. W., & Pagidipati, N. J. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01760-y · Cited by 15
Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
Bae, S., Ahn, J. B., Joseph, C., Whisler, R., Schnitzler, M. A., Lentine, K. L., KADOSH, B. S., Segev, D. L., & McAdams‐DeMarco, M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000124 · Cited by 13
Shahid, M., Gaines, A., Coyle, D. H., Alessandrini, R., Finnigan, T. J. A., Frost, G. S., Marklund, M., & Neal, B. C. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.03.019 · Cited by 16
Self-citationHuang, T., Wu, T., Fu, X., Ren, H., He, X., Zheng, D., Tan, J. H., Shen, C., Xiong, S., Jiang, Q., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103412 · Cited by 14
Metadata
- Authors
- Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., & Peto, R.
- Affiliations
- University of Oxford (GB)
- Johns Hopkins University (US)
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Wisconsin–Madison (US)
- University of London (GB)
- The University of Sydney (AU)
- Imperial College London (GB)
- Brigham and Women's Hospital (US)
- University of Edinburgh (GB)
- University of North Carolina at Chapel Hill (US)
- Population Health Research Institute (CA)
- Corresponding author
- Collins, Rory
- ORCID
- Collins, Rory
- Reith, Christina
- Emberson, Jonathan
- Armitage, Jane
- Baigent, Colin
- Blumenthal, Roger
- Danesh, John
- Smith, George Davey
- DeMets, David
- Evans, Stephen
- MacMahon, Stephen
- Martin, Seth
- Neal, Bruce
- Poulter, Neil
- Preiss, David
- Ridker, Paul
- Roberts, Ian
- Rodgers, Anthony
- Sandercock, Peter
- Schulz, Kenneth
- Smeeth, Liam
- Wald, Nicholas
- Yusuf, Salim
- Peto, Richard
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 388
- Issue
- 10059
- Pages
- 2532-2561
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2519634482
- Cited by
- 1,857
- References
- 299
- Citations by year
- 2026: 136 · 2025: 136 · 2024: 150 · 2023: 166 · 2022: 187 · 2021: 229 · 2020: 192 · 2019: 218 · 2018: 206 · 2017: 202 · 2016: 31
- FWCI
- 43.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Cancer Research UK (16896)
- National Institute for Health and Care Research (NF-SI-0611-10057, HTA/14/49/159, 14/49/159, NF-SI-0513-10059)
- British Heart Foundation (SP/08/010/25939, SP/14/3/31114, RG/13/13/30194)
- Medical Research Council (MR/K006584/1, MR/L003120/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- statin therapy, LDL cholesterol lowering, cardiovascular disease prevention, secondary prevention, primary prevention, absolute risk reduction, statin adverse effects, myopathy, rhabdomyolysis, new-onset diabetes, hemorrhagic stroke, atorvastatin, long-term treatment, evidence evaluation, cardiovascular risk assessment, cost-effectiveness, randomized controlled trials, meta-analysis
- MeSH terms
- Anticholesteremic Agents, Clinical Trials as Topic, Coronary Disease, Humans, Cholesterol, LDL, Myocardial Infarction, Safety, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
